These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 17912225)

  • 1. Cardiovascular disease in patients with chronic kidney disease. A clinical review.
    Kaisar M; Isbel N; Johnson DW
    Minerva Urol Nefrol; 2007 Sep; 59(3):281-97. PubMed ID: 17912225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease.
    Kaisar MO; Isbel NM; Johnson DW
    Rev Recent Clin Trials; 2008 May; 3(2):79-88. PubMed ID: 18474017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Clinical Trials of Pharmacologic Cardiovascular Interventions in Patients with Chronic Kidney Disease: An Update.
    Nataatmadja M; Cho Y; Fahim M; Johnson DW
    Rev Recent Clin Trials; 2016; 11(1):12-32. PubMed ID: 26497837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease.
    Kendrick J; Chonchol MB
    Nat Clin Pract Nephrol; 2008 Dec; 4(12):672-81. PubMed ID: 18825155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment?
    Scarpioni R; Ricardi M; Melfa L; Cristinelli L
    Cardiovasc Ther; 2010 Dec; 28(6):361-8. PubMed ID: 20553296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Epidemiology of cardiovascular disease in CKD-MBD].
    Di Micco L; Mozzillo GR; Cianciaruso B
    G Ital Nefrol; 2009; 26 Suppl 49():S3-10. PubMed ID: 19941272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease].
    Ravera M; Paoletti E
    Ital Heart J Suppl; 2004 Jun; 5(6):436-44. PubMed ID: 15471148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical epidemiology of cardiovascular disease in chronic kidney disease.
    Kundhal K; Lok CE
    Nephron Clin Pract; 2005; 101(2):c47-52. PubMed ID: 15942250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaemia and early phase cardiovascular events on haemodialysis.
    Hayashi T; Joki N; Tanaka Y; Hase H
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():1-6. PubMed ID: 26456311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anemia as a risk factor for CKD and CVD].
    Tsuruya K; Hirakata H
    Nihon Rinsho; 2008 Sep; 66(9):1786-93. PubMed ID: 18788410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of cardiovascular risk in hemodialysis patients: an evidence-based review.
    Johnson DW; Craven AM; Isbel NM
    Hemodial Int; 2007 Jan; 11(1):1-14. PubMed ID: 17257349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular disease and chronic kidney disease: insights and an update.
    Best PJ; Reddan DN; Berger PB; Szczech LA; McCullough PA; Califf RM
    Am Heart J; 2004 Aug; 148(2):230-42. PubMed ID: 15308992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anemia and the heart in chronic kidney disease.
    Zalunardo N; Levin A
    Semin Nephrol; 2006 Jul; 26(4):290-5. PubMed ID: 16949467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target hemoglobin level for EPO therapy in CKD.
    Parfrey PS
    Am J Kidney Dis; 2006 Jan; 47(1):171-3. PubMed ID: 16377399
    [No Abstract]   [Full Text] [Related]  

  • 16. Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: a meta-analysis of randomized controlled trials.
    Qin X; Huo Y; Xie D; Hou F; Xu X; Wang X
    Clin Nutr; 2013 Oct; 32(5):722-7. PubMed ID: 23313356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.
    Sjöberg B; Anderstam B; Suliman M; Alvestrand A
    Am J Kidney Dis; 2006 Jan; 47(1):60-71. PubMed ID: 16377386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing cardiovascular outcome in patients with renal impairment: is there a role for lipid-lowering therapy?
    Holdaas H
    Am J Cardiovasc Drugs; 2005; 5(4):255-69. PubMed ID: 15984908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic kidney disease (CKD) as an independent risk factor for cardiovascular disease (CVD)].
    Minami J; Ishimitsu T; Sudo Y; Matsuoka H
    Nihon Rinsho; 2008 Sep; 66(9):1657-63. PubMed ID: 18788391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.
    Mix TC; Brenner RM; Cooper ME; de Zeeuw D; Ivanovich P; Levey AS; McGill JB; McMurray JJ; Parfrey PS; Parving HH; Pereira BJ; Remuzzi G; Singh AK; Solomon SD; Stehman-Breen C; Toto RD; Pfeffer MA
    Am Heart J; 2005 Mar; 149(3):408-13. PubMed ID: 15864229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.